The Clinical Research Support (CRS) office serves as the principal mechanism for Clinical Protocol and Data Management (CPDM) in the Consortium. CRS facilitates the efficient review, approval, and implementation of cancer clinical research throughout the Consortium. CRS services include assistance throughout the protocol life cycle, including protocol development, navigation through review and approval processes, guidance and support in regulatory affairs, training and education, communications, registration of new trials with NCI CTRP, interim staffing, management of cooperative group trials, quality control and assurance, and data and safety management. In 2013, CRS supported 1168 studies, a 29% increase over 2008 and 23% of newly treated patients participated in a therapeutic clinical trial. Since CRS directly manages Consortium training, protocol submission through activation, protocol and consent form control, and provides other critical aspects of clinical trials, its impact to the Consortium's research base is exceptionally strong, and all investigators and study teams conducting clinical research use its services on an everyday basis through the life of a study. CRS staff members are organized into four interactive divisions: Study Implementation Support, Quality and Compliance, Study Support Services, and Data Management and Reporting. Data and safety monitoring encompasses all aspects of data monitoring, verifying data validity and integrity, and ensuring the safety of study participants in clinical trials and clinical trials are monitored based on degree of risk, size and complexity. Together, the Data Safety Monitoring Committee and its Compliance sub-committee ensure that investigator initiated trials are conducted according to all required policies and procedures in order to protect the rights and welfare of human subjects. The Consortium is committed to increasing the participation of minorities and children in clinical research by continuing to build trust and engagement with these populations in our catchment area. New initiatives are underway to minimize barriers to using the health care services of partner institutions, remove eligibility, recruitment or participation barriers, and find ways to encourage participation and retention for populations of all types.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-44
Application #
9617719
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Barault, Ludovic; Amatu, Alessio; Siravegna, Giulia et al. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67:1995-2005
Molina, Yamile; Briant, Katherine J; Sanchez, Janeth I et al. (2018) Knowledge and social engagement change in intention to be screened for colorectal cancer. Ethn Health 23:461-479
Winters, Brian R; Vakar-Lopez, Funda; Brown, Lisha et al. (2018) Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol Oncol 36:342.e7-342.e14
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Baker, K Scott; Syrjala, Karen L (2018) Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program 2018:146-153
Miller, Chris P; Tsuchida, Connor; Zheng, Ying et al. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:610-620
Paulson, K G; Voillet, V; McAfee, M S et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 9:3868
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215

Showing the most recent 10 out of 1267 publications